Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma
Phase 3 CARTITUDE-4 trial shows bridging therapy improves progression-free survival and safety in myeloma patients.
Key Points
To assess the correlation between response to bridging therapy and outcomes after ciltacabtagene autoleucel infusion.
CARTITUDE-4 trial assessed patients with relapsed lenalidomide-refractory multiple myeloma.
Patients received bridging therapy with either pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).
Apheresis was performed followed by lymphodepletion and cilta-cel infusion.
Average progression-free survival was improved across varying response levels post-bridging therapy.
Patients with better responses to bridging therapy had lower rates of cytopenia and infections.
30-month overall survival rates were significantly higher in patients with a very good partial response following bridging therapy.